Botanix Pharmaceuticals (ASX:BOT) said US payer organization Ascent Health will cover its Sofdra-branded sofpironium topical gel, 12.45%, for the treatment of primary axillary hyperhidrosis, or excessive sweating, according to a Thursday filing with the Australian bourse.
Ascent Health is the second largest payer in the US covering 65 million people, the filing said. The company is advancing reimbursement coverage deals with other payers.
Botanix Pharmaceuticals' shares rose past 6% in recent Thursday trade.
Price (AUD): $0.34, Change: $+0.02, Percent Change: +6.25%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments